Back to Search
Start Over
Ghrelin after chemotherapy as a prognostic predictor of progression-free survival in patients with muscle-invasive bladder cancer
- Source :
- Transl Androl Urol
- Publication Year :
- 2021
- Publisher :
- AME Publishing Company, 2021.
-
Abstract
- BACKGROUND: Although the patients with muscle-invasive bladder cancer (MIBC) generally have poor prognosis, the utility of these biomarkers for the prediction of oncological outcomes in MIBC has not been completely explored. Ghrelin regulates processes associated with cancer, including cell proliferation, apoptosis, cell migration, cell invasion, and angiogenesis. Thus, we aimed to evaluate the impact of serum ghrelin levels on survival in MIBC. METHODS: In this study, we reviewed the clinical and pathological records of 56 patients who were diagnosed with MIBC between November 2015 and November 2019 at Gifu and Hirosaki University Hospitals. We focused on 27 patients who had received chemotherapy and collected blood samples before and after chemotherapy. Blood samples were collected before chemotherapy and after completing two cycles of chemotherapy. Serum acyl (AG) and desacyl ghrelin (DG) were measured using AG and DG enzyme-linked immunosorbent assay kits (SCETI, Tokyo, Japan), respectively. RESULTS: The 3-year overall and progression-free survival (PFS) rates were 82.9% and 68.3%, respectively. According to the AG level after chemotherapy, the 3-year PFS rates were 77.5% and 53.0% in patients with AG levels ≥1.34 and
- Subjects :
- 0301 basic medicine
Oncology
medicine.medical_specialty
Chemotherapy
Predictive marker
Bladder cancer
Angiogenesis
business.industry
Urology
medicine.medical_treatment
Cancer
medicine.disease
03 medical and health sciences
030104 developmental biology
0302 clinical medicine
Reproductive Medicine
030220 oncology & carcinogenesis
Internal medicine
medicine
Original Article
Ghrelin
Progression-free survival
business
Pathological
Subjects
Details
- ISSN :
- 22234691 and 22234683
- Volume :
- 10
- Database :
- OpenAIRE
- Journal :
- Translational Andrology and Urology
- Accession number :
- edsair.doi.dedup.....f67462dc1550409c662e61f98ffa5e32